|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/502 | |
| A61K 9/22 | |||
| A61K 9/52 | |||
| A61P 35/00 | |||
| A61K 9/16 | |||
| A61K 9/20 | |||
| A61K 9/24 | |||
| A61K 9/50 |
| (11) | Patento numeris | 3556369 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17880064.5 |
| Europos patento paraiškos padavimo data | 2017-12-15 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-10-23 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-04-14 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2017/116475 |
| Data | 2017-12-15 |
| (87) | Numeris | WO 2018/108152 |
| Data | 2018-06-21 |
| (30) | Numeris | Data | Šalis |
| 201611168797 | 2016-12-16 | CN |
| (72) |
GAN, Yong, CN
ZHU, Quanlei, CN
GUO, Shiyan, CN
ZHU, Chunliu, CN
|
| (73) |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
555 Zu Chong Zhi Road Zhangjiang Hi-Tech Park Pudong New District, Shanghai 201203,
CN
|
| (54) | OLAPARIB ORAL SUSTAINED AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND USES THEREOF |
| OLAPARIB ORAL SUSTAINED AND CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION AND USES THEREOF |